<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39553825</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2948-1767</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Npj viruses</Title><ISOAbbreviation>Npj Viruses</ISOAbbreviation></Journal><ArticleTitle>Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">55</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s44298-024-00063-z</ELocationID><Abstract><AbstractText>SARS-CoV-2 continues to be a public health burden, driven in-part by its continued antigenic diversification and resulting emergence of new variants. By increasing herd immunity, current vaccines have improved infection outcomes for many. However, prophylactic and treatment interventions that are not compromised by viral evolution of the Spike protein are still needed. Using a differential staining strategy with a rationally designed SARS-CoV-2 Receptor Binding Domain (RBD) - ACE2 fusion protein and a native Omicron RBD protein, we developed a recombinant human monoclonal antibody (hmAb) from a convalescent individual following SARS-CoV-2 Omicron infection. The resulting hmAb, 1301B7 potently neutralized a wide range of SARS-CoV-2 variants including the original Wuhan-1, the more recent Omicron JN.1 strain, and SARS-CoV. 1301B7 contacts the ACE2 binding site of RBD exclusively through its VH1-69 heavy chain. Broad specificity is achieved through 1301B7 binding to many conserved residues of Omicron variants including Y501 and H505. Consistent with its extensive binding epitope, 1301B7 is able to potently diminish viral burden in the upper and lower respiratory tract and protect mice from challenge with Omicron XBB1.5 and Omicron JN.1 viruses. These results suggest 1301B7 has broad potential to prevent or treat clinical SARS-CoV-2 infections and to guide development of RBD-based universal SARS-CoV-2 prophylactic vaccines and therapeutic approaches.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Piepenbrink</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Khalil</LastName><ForeName>Ahmed Magdy</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX USA.</Affiliation><Identifier Source="ROR">https://ror.org/00wbskb04</Identifier><Identifier Source="GRID">grid.250889.e</Identifier><Identifier Source="ISNI">0000 0001 2215 0219</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.</Affiliation><Identifier Source="ROR">https://ror.org/053g6we49</Identifier><Identifier Source="GRID">grid.31451.32</Identifier><Identifier Source="ISNI">0000 0001 2158 2757</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Present Address: Department of Biomedical Sciences, The College of Medicine, Florida State University, Tallahassee, FL USA.</Affiliation><Identifier Source="ROR">https://ror.org/05g3dte14</Identifier><Identifier Source="GRID">grid.255986.5</Identifier><Identifier Source="ISNI">0000 0004 0472 0419</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Pacific Northwest University of Health Sciences, Yakima, WA USA.</Affiliation><Identifier Source="ROR">https://ror.org/008d6qw11</Identifier><Identifier Source="GRID">grid.449174.b</Identifier><Identifier Source="ISNI">0000 0004 0398 9002</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX USA.</Affiliation><Identifier Source="ROR">https://ror.org/00wbskb04</Identifier><Identifier Source="GRID">grid.250889.e</Identifier><Identifier Source="ISNI">0000 0001 2215 0219</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, 12622 Egypt.</Affiliation><Identifier Source="ROR">https://ror.org/02n85j827</Identifier><Identifier Source="GRID">grid.419725.c</Identifier><Identifier Source="ISNI">0000 0001 2151 8157</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Madhubanti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Sanghita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panjwani</LastName><ForeName>Simran</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Yaelyn H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX USA.</Affiliation><Identifier Source="ROR">https://ror.org/00wbskb04</Identifier><Identifier Source="GRID">grid.250889.e</Identifier><Identifier Source="ISNI">0000 0001 2215 0219</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Chengjin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX USA.</Affiliation><Identifier Source="ROR">https://ror.org/00wbskb04</Identifier><Identifier Source="GRID">grid.250889.e</Identifier><Identifier Source="ISNI">0000 0001 2215 0219</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY USA.</Affiliation><Identifier Source="ROR">https://ror.org/04jdq2t93</Identifier><Identifier Source="GRID">grid.280587.0</Identifier><Identifier Source="ISNI">0000 0004 0421 0304</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Todd J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kizziah</LastName><ForeName>James L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdmann</LastName><ForeName>Nathaniel B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goepfert</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY USA.</Affiliation><Identifier Source="ROR">https://ror.org/04jdq2t93</Identifier><Identifier Source="GRID">grid.280587.0</Identifier><Identifier Source="ISNI">0000 0004 0421 0304</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY USA.</Affiliation><Identifier Source="ROR">https://ror.org/04jdq2t93</Identifier><Identifier Source="GRID">grid.280587.0</Identifier><Identifier Source="ISNI">0000 0004 0421 0304</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Sobrido</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX USA.</Affiliation><Identifier Source="ROR">https://ror.org/00wbskb04</Identifier><Identifier Source="GRID">grid.250889.e</Identifier><Identifier Source="ISNI">0000 0001 2215 0219</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobie</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL USA.</Affiliation><Identifier Source="ROR">https://ror.org/008s83205</Identifier><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000 0001 0634 4187</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Npj Viruses</MedlineTA><NlmUniqueID>9918716188906676</NlmUniqueID><ISSNLinking>2948-1767</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Competing interestsM.S.P., A.M.K., A.C., M.B., S.S., S.P., N.B.E., P.A.G., M.R.W., L.M.-S., and J.J.K. are co-inventors on patent applications that include claims related to the hmAbs described in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39553825</ArticleId><ArticleId IdType="pmc">PMC11564104</ArticleId><ArticleId IdType="doi">10.1038/s44298-024-00063-z</ArticleId><ArticleId IdType="pii">63</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holshue, M. L. et al. First Case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med.382, 929–936 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO COVID-19 dashboard. 2024 [cited 2024]Available from: https://data.who.int/dashboards/covid19/deaths?n=c.</Citation></Reference><Reference><Citation>Arabi, M. et al. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review. BMC Infect. Dis.23, 432 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10294418</ArticleId><ArticleId IdType="pubmed">37365490</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun.15, 2254 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis.24, e82 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38184005</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, P. et al. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. Cell Rep.43, 114520 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11430188</ArticleId><ArticleId IdType="pubmed">39024099</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W. et al. Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins. EMBO J.43, 1484–1498 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11021471</ArticleId><ArticleId IdType="pubmed">38467833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion. iScience27, 109904 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11134884</ArticleId><ArticleId IdType="pubmed">38812550</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande, A. et al. Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of beta coronaviruses. FEBS J.290, 3422–3435 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10330828</ArticleId><ArticleId IdType="pubmed">37014961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju, B. et al. Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1. Natl Sci. Rev.10, nwad148 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10309178</ArticleId><ArticleId IdType="pubmed">37396140</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, Y. et al. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine. Sci. Transl. Med15, eadg7404 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032722</ArticleId><ArticleId IdType="pubmed">37163615</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenthoer, J. et al. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. Proc. Natl Acad. Sci. USA120, e2220948120 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10265947</ArticleId><ArticleId IdType="pubmed">37253011</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature583, 290–295 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, P. S. et al. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat. Commun.5, 3614 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358779</ArticleId><ArticleId IdType="pubmed">24717798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, F., Tzarum, N., Wilson, I. A. &amp; Law, M. V(H)1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr. Opin. Virol.34, 149–159 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266006</ArticleId><ArticleId IdType="pubmed">30884330</ArticleId></ArticleIdList></Reference><Reference><Citation>He, P. et al. SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. Nat. Microbiol7, 1635–1649 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9519457</ArticleId><ArticleId IdType="pubmed">36151403</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. &amp; Rombouts, Y. The Emerging Importance of IgG Fab Glycosylation in Immunity. J. Immunol.196, 1435–1441 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26851295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. &amp; Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev. Immunol.25, 21–50 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17029568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, A., Tao, M. H., Kabat, E. A. &amp; Morrison, S. L. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J.10, 2717–2723 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452979</ArticleId><ArticleId IdType="pubmed">1717254</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Bovenkamp, F. S. et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc. Natl. Acad. Sci. USA115, 1901–1906 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828577</ArticleId><ArticleId IdType="pubmed">29432186</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma, M. J., Trinh, R. K., Martinez, A. R. &amp; Morrison, S. L. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-&gt;6) dextran antibody. J. Immunol.162, 2162–2170 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9973491</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, R., Oren, D. A., Franco, D., Seaman, M. S. &amp; Ho, D. D. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat. Biotechnol.31, 1047–1052 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3825789</ArticleId><ArticleId IdType="pubmed">24097413</ArticleId></ArticleIdList></Reference><Reference><Citation>de Campos-Mata, L. et al. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity. Nat. Commun.15, 1051 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10844294</ArticleId><ArticleId IdType="pubmed">38316751</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, Y. et al. A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice. Microbiol Spectr.11, e0419422 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10100915</ArticleId><ArticleId IdType="pubmed">36912685</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi, Z. A. et al. Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice. Commun. Biol.6, 935 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10499788</ArticleId><ArticleId IdType="pubmed">37704701</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepenbrink, M. S. et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep. Med2, 100218 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904445</ArticleId><ArticleId IdType="pubmed">33649747</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepenbrink, M. S. et al. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog.18, e1010691 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302814</ArticleId><ArticleId IdType="pubmed">35862475</ArticleId></ArticleIdList></Reference><Reference><Citation>Streblow, D. N. et al. Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. Nat. Commun.14, 7062 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10624670</ArticleId><ArticleId IdType="pubmed">37923717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogales, A. et al. A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci. Rep.8, 4374 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847613</ArticleId><ArticleId IdType="pubmed">29531320</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu, M. et al. Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. Cell Rep. Med1, 100015 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311075</ArticleId><ArticleId IdType="pubmed">32577626</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, J. G. et al. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. J. Virol. Methods287, 113995 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554492</ArticleId><ArticleId IdType="pubmed">33068703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell186, 279–286.e278 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani, A., Rubinstein, J. L., Fleet, D. J. &amp; Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods14, 290–296 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintilie, G. D., Zhang, J., Goddard, T. D., Chiu, W. &amp; Gossard, D. C. Quantitative analysis of cryo-EM density map segmentation by watershed and scale-space filtering, and fitting of structures by alignment to regions. J. Struct. Biol.170, 427–438 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874196</ArticleId><ArticleId IdType="pubmed">20338243</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci.32, e4792 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588335</ArticleId><ArticleId IdType="pubmed">37774136</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley, P. &amp; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr60, 2126–2132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D. Struct. Biol.74, 531–544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>The PyMOL Molecular Graphics System. 3.0 ed: Schrödinger, LLC.</Citation></Reference><Reference><Citation>Khalil, A. M. et al. Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody. Viruses15, 1540 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10383564</ArticleId><ArticleId IdType="pubmed">37515226</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande, A., Harris, B. D., Martinez-Sobrido, L., Kobie, J. J. &amp; Walter, M. R. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Front Immunol.12, 691715 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212047</ArticleId><ArticleId IdType="pubmed">34149735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>